PRGO:NYE-Perrigo Company PLC (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 25.32

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.85M

Analyst Target

USD 57.88
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-20 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

N/A

USD 66.32B
HLN Haleon plc

N/A

USD 45.41B
TAK Takeda Pharmaceutical Co Ltd A..

N/A

USD 43.84B
RDY Dr. Reddy’s Laboratories Ltd..

N/A

USD 11.39B
ELAN Elanco Animal Health

N/A

USD 4.28B
AMRX Amneal Pharmaceuticals, Inc. C..

N/A

USD 3.25B
BHC Bausch Health Companies Inc

N/A

USD 1.60B
CPHI China Pharma Holdings Inc

N/A

USD 4.61M
YCBD cbdMD Inc

N/A

USD 1.44M
EBS Emergent Biosolutions Inc

N/A

N/A

ETFs Containing PRGO

FLWR:SW 15.27 % 0.00 %

N/A

N/A
XMET:AU BetaShares Energy Transit.. 4.93 % 0.00 %

N/A

N/A
LIMI Themes Lithium & Battery .. 3.86 % 0.00 %

N/A

USD 0.49M
GNRX 0.00 % 0.55 %

N/A

N/A
PILL Direxion Daily Pharmaceut.. 0.00 % 0.98 %

N/A

N/A
XPH SPDR® S&P Pharmaceutical.. 0.00 % 0.35 %

N/A

N/A
ISRL:LSE 0.00 % 0.00 %

N/A

N/A
TASE:LSE 0.00 % 0.00 %

N/A

N/A
QDVM:F 0.00 % 0.00 %

N/A

N/A
QDVM:XETRA 0.00 % 0.00 %

N/A

N/A
WSRD:CA Wealthsimple Developed Ma.. 0.00 % 0.00 %

N/A

CAD 0.81B
FLWG:LSE 0.00 % 0.00 %

N/A

N/A
FLWR:LSE 0.00 % 0.00 %

N/A

N/A
BLUM:XETRA 0.00 % 0.00 %

N/A

N/A
HLIT:CA Global X Lithium Producer.. 0.00 % 0.00 %

N/A

CAD 0.02B
BLUM:F 0.00 % 0.00 %

N/A

N/A
ION Proshares S&P Global Core.. 0.00 % 0.00 %

N/A

USD 2.31M

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.52% 71% C- 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.52% 71% C- 64% D
Trailing 12 Months  
Capital Gain -17.79% 29% F 18% F
Dividend Return 2.69% 50% F 47% F
Total Return -15.10% 29% F 18% F
Trailing 5 Years  
Capital Gain -49.04% 46% F 8% B-
Dividend Return 9.80% 40% F 21% F
Total Return -39.24% 46% F 8% B-
Average Annual (5 Year Horizon)  
Capital Gain -12.97% 7% C- 5% F
Dividend Return -10.47% 7% C- 5% F
Total Return 2.51% 83% B 56% F
Risk Return Profile  
Volatility (Standard Deviation) 8.05% 100% F 83% B
Risk Adjusted Return -130.08% 7% C- N/A F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector